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 is the chief cause of pneumonia in older adults, but it remains
unclear whether use of the pneumococcal polysaccharide vaccine alters the overall risk
of community-acquired pneumonia. In a large population of older adults, we assessed




In this retrospective cohort study, 47,365 Group Health Cooperative members 65 years
of age or older were assessed over a three-year period. The primary outcomes were hos-
pitalization because of community-acquired pneumonia (validated by chart review),
pneumonia in patients who were not hospitalized (“outpatient pneumonia,” determined
from administrative data sources), and pneumococcal bacteremia. The association be-
tween pneumococcal vaccination and the risk of each outcome was evaluated by means
of multivariate Cox proportional-hazards models, with adjustment for age, sex, nursing-
home residence or nonresidence, smoking status, medical conditions, and receipt or




During the study period, 1428 cohort members were hospitalized with community-
acquired pneumonia, 3061 were assigned a diagnosis of outpatient pneumonia, and
61 had pneumococcal bacteremia. Receipt of the pneumococcal vaccine was associated
with a significant reduction in the risk of pneumococcal bacteremia (hazard ratio, 0.56;
95 percent confidence interval, 0.33 to 0.93) but a slightly increased risk of hospital-
ization for pneumonia (hazard ratio, 1.14; 95 percent confidence interval, 1.02 to 1.28).
Pneumococcal vaccination did not alter the risk of outpatient pneumonia (hazard ratio,
1.04; 95 percent confidence interval, 0.96 to 1.13) or of any case of community-acquired
pneumonia, whether or not it required hospitalization (hazard ratio, 1.07; 95 percent




These findings support the effectiveness of the pneumococcal polysaccharide vaccine
for the prevention of bacteremia, but they suggest that alternative strategies are needed
to prevent nonbacteremic pneumonia, which is a more common manifestation of pneu-
mococcal infection in elderly persons.
abstract
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hospitalizations each year among persons
65 years of age and older in the United States, and
in that group the category of pneumonia and influ-









 is the most common cause of commu-





vaccine that protected against pneumococcal pneu-
monia could reduce the risk of community-acquired
pneumonia in this group. Since the majority of cas-





 an effect of vaccination against
community-acquired pneumonia would probably
be evident only if the vaccine provided protection
against nonbacteremic pneumococcal infections.
A retrospective cohort study of 1898 older adults
with chronic lung disease showed that the 23-valent
pneumococcal polysaccharide vaccine was associ-
ated with a significant reduction in the risk of hos-





multiple prospective clinical trials of pneumococcal





 failed to document a reduction in









than 1500 vaccinated subjects and therefore had a
limited ability to detect a true effect of the vaccine.
It is therefore not clear whether the 23-valent
pneumococcal polysaccharide vaccine reduces the
risk of pneumonia in older adults. This is an impor-
tant question, because other pneumococcal vaccine
formulations, such as the protein conjugate vaccine
now recommended for universal immunization of
















 To evaluate the effec-
tiveness of pneumococcal polysaccharide vaccine
against community-acquired pneumonia, as well as
the more specific outcome of pneumococcal bacte-
remia, we conducted a population-based retrospec-
tive cohort study of more than 47,000 persons 65




The study population consisted of members of the
Group Health Cooperative, a health maintenance
organization (HMO) in Washington State, who were
at least 65 years of age on March 1, 1998 (the date
of the start of the study) and who had been enrolled
for at least one year before that date. Cohort mem-
bers were followed until death, disenrollment from
the HMO, or the end of the study on February 28,
2001, whichever came first. The institutional review
board of Group Health Cooperative approved the
study and certified that it met the criteria for a waiv-
er of the requirement to obtain informed consent.
 




The Group Health Cooperative maintains adminis-
trative data bases that record immunizations, labo-
ratory tests, radiographic procedures, medication
prescriptions, and diagnoses associated with out-
patient visits and hospitalizations, which are coded
according to the 
 
International Classification of Diseases,







member also has a paper medical record that con-
tains copies of dictated hospital admission and dis-
charge summaries, notes on outpatient and emer-




Coronary artery disease, chronic lung disease, di-
abetes mellitus, dementia or stroke, and immu-
nosuppression were defined on the basis of ICD-9-
CM codes, prescriptions for medication, and the
patient’s status in disease registries. Immunosup-
pression was a composite variable defined by the
presence of any one of the following: cancer, use of
immunosuppressive medications, chronic liver dis-
ease, or chronic renal disease. Smoking status was





 A detailed description of the
classification of covariates is available as Supple-





The Group Health Cooperative immunization data
base, established in 1991, was used to identify pneu-
mococcal and influenza vaccinations. To identify
pneumococcal vaccinations recorded in the paper
medical record but not in the immunization data
base, such as those administered before 1991, the
medical record was reviewed for all cohort members
who did not have a record of pneumococcal vacci-
nation in the data base.
c
methods
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The primary outcomes were hospitalization for
community-acquired pneumonia, pneumonia in
patients who were not hospitalized (outpatient
pneumonia), and pneumococcal bacteremia. Hos-
pitalizations for pneumonia and hospitalizations
for pneumococcal bacteremia were presumptively
identified on the basis of ICD-9-CM discharge
codes (480 through 487.0 for pneumonia and 038.0,
038.2, 041.0, 041.2, and 320.1 for bacteremia). Cas-
es of pneumococcal bacteremia were also identified
from Group Health Cooperative laboratory data.
Both outcomes were validated by review of the pa-
per medical record with the use of a standardized
data-collection instrument. A hospitalization was
considered to be due to community-acquired pneu-
monia if, at the conclusion of the clinical evaluation,
the treating physician considered pneumonia to be
the cause of the presenting illness. The two sets of
chart reviews — one for validation of outcome
events and the other for vaccination status — were
conducted at different times.
Outpatient pneumonia was defined as an outpa-
tient or emergency room visit with an ICD-9-CM
code for pneumonia (480 to 487.0) that was asso-
ciated with both a prescription for an antibiotic
and chest radiography within 14 days before or af-
ter the visit.
So as to permit comparison with other published
studies, hospitalization with a discharge diagnosis
code for pneumonia (regardless of the chart-valida-
tion status of the events) and death from any cause




Crude event rates were calculated by dividing the
number of cases by the person-time for each out-
come, with person-time censored after the occur-
rence of a first event. Multivariate Cox proportional-





used to evaluate the association between the receipt
of pneumococcal vaccine and the time to a first out-
come event during the study period. Pneumococcal-
vaccination status was a time-varying covariate, and
persons were considered to be vaccinated begin-
ning 14 days after administration of the vaccine.
The models were adjusted for age at study entry;
sex; nursing-home residence or nonresidence; re-
ceipt or nonreceipt of influenza vaccine; smoking
status (currently smoking, not currently smoking,
or no data); presence or absence of diabetes melli-
tus, coronary artery disease, immunosuppression,
chronic lung disease, dementia or stroke, and hos-
pitalization for pneumonia in the year before study
entry; and number of outpatient visits in the year
before study entry. Because the proportion of sub-
jects with data on smoking status varied significant-
ly according to pneumococcal-vaccination status at
study entry, alternative analyses excluded subjects
with no data on smoking status. Nursing-home res-
idence or nonresidence and receipt or nonreceipt
of influenza vaccine were time-varying covariates,
whereas the other covariates were defined at study
entry. Persons were classified as vaccinated with re-
spect to influenza from 14 days after administration
of the vaccine through the end of the corresponding
influenza season, as defined on the basis of local




characteristics of the study subjects
 
The cohort consisted of 47,365 persons who were
observed for a total of 127,180 person-years, of
which 84,203 person-years (66 percent) followed
pneumococcal vaccination. Of the 26,313 persons
vaccinated before the beginning of the study (Table
1), 23,996 (91 percent) received pneumococcal vac-
cine most recently on or after their 65th birthdays,
and 21,323 (81 percent) had been vaccinated with-
in five years before the beginning of the study. Of
the 21,052 persons who had not received pneumo-
coccal vaccine before study entry, 10,869 (52 per-




A total of 2833 hospitalizations (of 2436 patients)
were assigned an ICD-9-CM code for pneumonia
(codes 480 through 487.0), and information on 2636
of these hospitalizations (93 percent) was available
for review. Forty-eight of these were readmissions
of patients with pneumonia, and 133 were associ-
ated with nosocomially acquired pneumonia. Of the
remaining 2455 hospitalizations, a clinical diagno-
sis of community-acquired pneumonia was con-
firmed for 1600 (65 percent), which were accounted
for by 1421 patients. An additional seven persons
had an episode of community-acquired pneumonia,
identified by chart review, during a hospitalization
associated with an ICD-9-CM code for bacteremia.
Thus, 1428 persons had a first hospitalization with
confirmed community-acquired pneumonia during
the study period. Sixty-one had pneumococcal bac-
teremia. During the study period, 3061 persons had
results
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at least one episode of outpatient pneumonia, and





In multivariate analyses of data on all subjects, re-
ceipt of pneumococcal vaccine was associated with
a 44 percent reduction in the risk of pneumococcal
bacteremia (Table 2). There was no significant as-
sociation between vaccination and the risk of out-
patient pneumonia or death, but vaccination was
associated with a significantly higher risk of hospi-
talization with community-acquired pneumonia.
In the analysis excluding the 13 percent of subjects
with no data on smoking, this association was no
longer statistically significant. There was no signif-
icant association between vaccination and all cases
of community-acquired pneumonia, defined as a
composite variable including both hospitalization
for community-acquired pneumonia and outpatient
pneumonia (hazard ratio, 1.07; 95 percent confi-
dence interval, 0.99 to 1.14).
The relation of pneumococcal vaccination to the
risk of outcome events did not vary according to the
time since vaccination. For example, there was no
consistent variation in the risk of hospitalization
with community-acquired pneumonia that was as-
sociated with vaccination within an interval of 0 to
11 months (hazard ratio, 1.08; 95 percent confi-
dence interval, 0.87 to 1.33), 12 to 23 months (haz-
ard ratio, 1.23; 95 percent confidence interval, 1.02
to 1.49), 24 to 35 months (hazard ratio, 0.97; 95 per-
cent confidence interval, 0.79 to 1.19), and 36 or
more months (hazard ratio, 1.18; 95 percent confi-
dence interval, 1.04 to 1.34), as compared with the
reference group of persons who were not vacci-
nated.
In multivariate analyses, influenza vaccination
was associated with a significant reduction in the
risk of hospitalization with community-acquired
pneumonia (hazard ratio, 0.78; 95 percent confi-
dence interval, 0.65 to 0.95) and the risk of death
(hazard ratio, 0.68; 95 percent confidence interval,
0.62 to 0.76) during influenza seasons, but it was
not associated with the occurrence of outpatient
pneumonia (hazard ratio, 1.12; 95 percent confi-
dence interval, 0.97 to 1.30) or pneumococcal bac-
teremia (hazard ratio, 0.92; 95 percent confidence
interval, 0.38 to 2.25) during influenza seasons.
In analyses restricted to immunocompetent per-
sons who received influenza vaccine for each in-
fluenza season during which they remained in the
cohort, pneumococcal vaccination was not associ-
ated with a reduction in the risk of hospitalization
with pneumonia or of outpatient pneumonia. This
result suggests that there is no added benefit of
pneumococcal vaccination against those outcomes;
however, pneumococcal vaccination was associated
with a significant reduction in the risk of death (Ta-
ble 3). Among immunocompetent persons with
 
* P values were calculated with the chi-square test.
† The median ages of the unvaccinated and vaccinated subjects were 74.7 and 
74.5 years, respectively.
‡ The median duration of enrollment in the Group Health Cooperative for un-
vaccinated and vaccinated subjects was 17.1 and 19.1 years, respectively.
§ Pneumonia was defined by hospital-discharge codes 480 through 487.0 of the 
 




Table 1. Base-Line Characteristics of 47,365 Cohort Members According to 
























Male sex 8,747 (41.5) 11,007 (41.8) 0.54
Duration of enrollment in 
























Coronary artery disease 3,843 (18.3) 5,911 (22.5) <0.001
Immunocompromised 4,012 (19.1) 5,351 (20.3) <0.001
Diabetes mellitus 2,394 (11.4) 4,654 (17.7) <0.001
Chronic lung disease 1,702 (8.1) 2,839 (10.8) <0.001
Dementia or stroke 1,150 (5.5) 1,385 (5.3) 0.34













in previous 12 mo§
219 (1.0) 319 (1.2) 0.079
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chronic lung disease, the condition most strongly
associated with an increased risk of pneumonia in
the multivariate models, there was no association
between pneumococcal vaccination and the risk of
pneumonia outcomes or death, but there was a re-
duction in the risk of pneumococcal bacteremia of
borderline statistical significance.
In this retrospective study of a large cohort of 47,365
older adults, we did not identify an association be-
tween pneumococcal vaccination and a reduced risk
of community-acquired pneumonia from any cause.




 was a common
cause of pneumonia in this population, we infer
from these results that vaccination was not highly
protective against pneumococcal pneumonia with-
out bacteremia. The association between vaccina-
tion and the specific outcome of pneumococcal
pneumonia without bacteremia could not be direct-
ly assessed, because an etiologic agent is not iden-
tified for most cases of pneumonia. Our results are
consistent with those of four meta-analyses of pro-
spective randomized trials of pneumococcal poly-
saccharide vaccines, all of which concluded that
there is no evidence that the vaccine is associated
with a reduction in the risk of pneumonia from any




The analysis of our most specific outcome —
pneumococcal bacteremia — indicated a reduc-
tion in risk that is consistent with the results of
other studies. Our point estimate of vaccine effec-
tiveness of 44 percent (95 percent confidence in-
terval, 7 to 67 percent) is similar to the 47 percent
estimate (95 percent confidence interval, 30 to 59





 Since pneumococcal polysaccha-
ride vaccine is recommended for all persons 65
years of age or older on the basis of evidence of its









results support the continued use of the vaccine in
older adults for the prevention of invasive pneu-
mococcal disease.
The size of our study, in terms of the total years
of follow-up time and the number of pneumonia
events observed, is a strength. The rate of hospital-
ization with community-acquired pneumonia that
we observed, approximately 11 hospitalizations per
discussion
 
* The hazard ratios are for vaccinated subjects as compared with unvaccinated subjects. The multivariate hazard ratios were adjusted for age 
(65 to 74, 75 to 84, or more than 84 years); sex; nursing-home residence or nonresidence; receipt or nonreceipt of influenza vaccine; smoking 
status (currently smoking, not currently smoking, or no data); presence or absence of coronary artery disease, immunocompromised status, 
diabetes mellitus, chronic lung disease, and dementia or stroke; number of outpatient visits in the year before cohort entry (fewer than 6, 6 to 






International Classification of Diseases, 9th Revision, Clinical Modification
 




‡ The analysis excludes 6343 subjects for whom no data on smoking were available.
 












































Multivariate-adjusted hazard ratio 












Multivariate-adjusted hazard ratio for 
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1000 person-years, is similar to the rate of 10 per
1000 person-years reported for persons 65 years of




The rate of pneumococcal bacteremia among un-
vaccinated cohort members in this study, 68 per
100,000 person-years, is similar to the overall rate
of 58 per 100,000 person-years for persons 65
years of age or older reported by the Active Bacterial





 These similar event rates
support the validity of our case-finding and out-
come-validation methods.
On the basis of the event rates, our study had a
power of 76 percent to detect a 15 percent reduc-
tion in the risk of hospitalization because of com-
munity-acquired pneumonia and a power of 98
percent to detect a 15 percent reduction in the risk
of outpatient pneumonia associated with vaccina-
tion. On the assumption that 30 percent of cases of







 a 50 percent reduction in the risk of pneumo-
coccal pneumonia would result in a 15 percent re-
duction in the risk of pneumonia from any cause.
On the basis of this assumption, these estimates
reflect the power of the study to detect at least a 50




 associated with vaccination. Our fail-
ure to detect such a decrease in risk does not exclude
the possibility that the vaccine had some effect
against pneumococcal pneumonia without bacte-
remia. Rather, it implies that, at a population level,
the use of the pneumococcal polysaccharide vaccine
 
* The hazard ratios are for vaccinated subjects as compared with unvaccinated subjects and were adjusted, where appropriate, for age (65 to 
74, 75 to 84, or more than 84 years); sex; nursing-home residence or nonresidence; receipt or nonreceipt of influenza vaccine; smoking status 
(currently smoking, not currently smoking, or no data); presence or absence of coronary artery disease, diabetes mellitus, chronic lung dis-
ease, and dementia or stroke; number of outpatient visits in the year before study entry (fewer than 6, 6 to 12, or more than 12); and any hos-
pitalization for pneumonia in the year before cohort entry. CI denotes confidence interval, and ICD-9-CM the 
 
International Classification of Dis-




† The hazard ratio was not adjusted for receipt or nonreceipt of influenza vaccine, sex, smoking status, presence or absence of dementia or 
stroke, and number of outpatient visits in the year before study entry because there were too few events to allow these variables to be estimat-
 
ed in the model.
 
Table 3. Risk of Pneumonia, Pneumococcal Bacteremia, and Death from Any Cause According to Pneumococcal-Vaccination Status 
















Hospitalization for community-acquired pneu-
monia verified by medical-record review
No. of events
Multivariate-adjusted hazard ratio (95% CI)















Multivariate-adjusted hazard ratio (95% CI)















Multivariate-adjusted hazard ratio (95% CI)













Hospitalization with a discharge diagnosis of 
pneumonia (ICD-9-CM codes 480 
through 487.0)
No. of events
Multivariate-adjusted hazard ratio (95% CI)













Death from any cause
No. of events
Multivariate-adjusted hazard ratio (95% CI)
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is unlikely to have a meaningful effect on the occur-
rence of community-acquired pneumonia among
persons 65 years of age or older.
Our findings contrast with those of another ret-
rospective study, which involved 1898 patients with





 In that study, receipt of pneumo-
coccal vaccine, as defined by administrative data,
was associated with significant reductions in the
risk of hospitalization for pneumonia and influen-
za, as defined by ICD-9-CM codes 480 through 487
(risk ratio, 0.57; 95 percent confidence interval,
0.38 to 0.84). Our results are not consistent with
these findings, even when the data are analyzed for
the subgroup of 3126 immunocompetent persons
with chronic lung disease, as defined by our crite-
ria (Table 3). The reasons for the disparate findings
may include differences in the patterns of vaccine
use, the methods of ascertainment of vaccination
status, or the prevalence of pneumococcal pneumo-
nia in the two study populations.
Ours is an observational study and is subject to
the limitations of a nonrandomized study design.
We obtained information on smoking status, nurs-
ing-home residence or nonresidence, and the pres-
ence or absence of chronic medical conditions from
administrative data bases in an attempt to control
for factors that could influence the relation between
vaccination and the risk of outcome events. Ascer-
tainment of medical conditions from administra-





 and these methods do not allow patients
to be classified according to the severity of their ill-
ness. Although we did control for the number of
outpatient visits in the year before study entry as a
proxy marker of the severity of illness, it is possible
that residual confounding influenced our estimates
of the association between vaccination and the risk
of disease.
We found that pneumococcal vaccination was
associated with a significant increase in the risk of
hospitalization with community-acquired pneumo-
nia, as verified by review of medical records, in the
analysis of all subjects and a nonsignificant increase
in this risk in some subgroup analyses. Of relevance
to these findings are the results of a randomized,
placebo-controlled trial of 23-valent pneumococcal
polysaccharide vaccine in adults infected with the
human immunodeficiency virus (HIV) in Uganda.
In that trial, there was a significantly increased risk
of invasive pneumococcal disease caused by vac-
cine serotypes within six months after vaccination
among persons who had received the vaccine, as
well as an increased risk of the overlapping outcome
of pneumonia from any cause during that period
(approximately a third of cases of pneumonia from





 The reasons for the increased risks as-
sociated with vaccination in the study in Uganda are
not well defined, and an increased risk of disease
has not been found in two observational studies of
pneumococcal polysaccharide vaccine among HIV-




We found a reduced risk of pneumococcal bac-
teremia, the outcome most directly linked to pneu-
mococcal infection, among vaccinated persons and
no relation between the risk of hospitalization be-
cause of community-acquired pneumonia and the
time since vaccination. We found no association
between vaccination and the risk of outpatient pneu-
monia. Although these factors suggest a nonbio-
logic basis for the observed association between
vaccination and the increased risk of hospitaliza-
tion because of community-acquired pneumonia in
our study, such as chance variation or the influence
of residual confounding, the possibility of a true vac-
cine effect cannot be completely excluded.
Our results support the use of pneumococcal
polysaccharide vaccine to prevent bacteremic dis-
ease in adults aged 65 years or over. The lack of ev-
idence of effectiveness against pneumonia without
bacteremia, however, underscores the critical need
to evaluate other vaccine formulations for the pre-
vention of noninvasive pneumococcal infections in
adults. Two such possibilities are protein conju-
gate pneumococcal vaccines, such as the licensed
7-valent formulation recommended for use in young











 which may also offer the advan-
tage of greater mucosal immunity than is conferred
by polysaccharide vaccines.
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